TMC125: important one-year trial now recruiting in U.S.
An new NNRTI that greatly reduces HIV resistance to this major class of drugs is now recruiting at about 50 U.S. medical centers. It is active against virus resistant to efavirenz and nevirapine.
James
John S
JS
D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D009570:Nitriles; D011724:Pyridazines / Q000627:therapeutic use*; D011743:Pyrimidines; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D014481:United States
D009570:Nitriles; D011724:Pyridazines; D011743:Pyrimidines; D018894:Reverse Transcriptase Inhibitors; C451734:etravirine